Clinicopathological significance of combined immunohistochemical analysis of PTEN, p53 and EGFR in breast carcinoma
10.13315/j.cnki.cjcep.2015.09.006
- VernacularTitle:联合检测乳腺癌组织中 PTEN、p53和 EGFR表达的临床病理意义
- Author:
Xinjun LI
;
Limei FU
;
Mingxia FU
;
Dong XUE
- Publication Type:Journal Article
- Keywords:
breast neoplasm;
PTEN;
p53;
EGFR;
immunohistochemistry
- From:
Chinese Journal of Clinical and Experimental Pathology
2015;(9):986-990
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To study clinical pathological significance of the expression of PTEN, p53 and epidermal growth factor receptor ( EGFR) in breast carcinoma and their correlation. Methods Immunohistochemical MaxVision method was used to detect the expres-sion of PTEN, p53, EGFR in 209 cases of infiltrating ductal carcinoma of breast and 40 cases of benign breast diseases. Results The over-expression rate of PTEN, p53 and EGFR protein in breast carcinoma was 57. 9%, 55. 0% and 38. 3% respectively, which was significantly different from those in benign breast diseases (P<0. 05). The expression of PTEN, p53 and EGFR in breast cancer was correlated with tumor size, histological grade, lymph node metastasis, ER status, PR status and molecular subtype (P<0. 05). There was an association between PTEN or p53 and TNM stage, PTEN or EGFR and HER-2 status. There was a negative correlation in the protein expression of PTEN vs EGFR or PTEN vs p53 (P<0. 01). There was a positive correlation between EGFR and p53 protein ex-pression (P=0. 000). The expression of PTEN or EGFR was correlated with the prognosis of breast cancer, but not independent prog-nostic factors. The survival rate of patients with PTEN- /p53 + /EGFR+ was lower than those with other combined expression of PTEN/p53/EGFR (P=0. 008). Conclusions Low or loss expression of PTEN, p53 mutation and EGFR over-expression may be coordinate-ly involved in the pathogenesis and progression of breast cancer. The combined detection of these markers may play an important role in making treatment and indicating prognosis for breast cancer patients.
